MGTX
MeiraGTx Holdings plcNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-128.55
P/S
9.08
EV/EBITDA
-9.07
DCF Value
$-45.58
FCF Yield
-7.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
94.0%
Operating Margin
-130.2%
Net Margin
-140.3%
ROE
4438.9%
ROA
-46.8%
ROIC
-70.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $75.4M | $15.1M | $0.19 |
| FY 2025 | $81.4M | $-114.2M | $-1.42 |
| Q3 2025 | $410.0K | $-50.5M | $-0.62 |
| Q2 2025 | $3.7M | $-38.8M | $-0.48 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.28
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.